Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

ERP N1 as a Treatment Predictor of Generalized Anxiety Disorder (N1)

This study has been completed.
Information provided by:
Inje University Identifier:
First received: January 29, 2008
Last updated: June 29, 2010
Last verified: June 2010

Amplitude changes of the N1 and the N1/P2 ERP component in response to different tone intensities have been suggested as a correlative of central serotonergic activity. A strong loudness dependence amplitude increase (strong intensity dependence) reflects low serotonergic neurotransmission and vice versa. Many researchers assumed that the brain serotonergic activity could influence treatment response of highly selective serotonin reuptake inhibitors in depression and anxiety disorders. There are a couple of studies reporting associations of N1 amplitude intensity dependence with response to Citalopram (positive correlation) and Reboxetine (negative correlation) treatment in major depressive disorder patients. But so far there have been no reports about associations between ERP N1 and antidepressant response in GAD patients.

So, it would be very interesting to explore the correlations between ERP N1 amplitude change and the Escitalopram treatment responsiveness in GAD patients.

Condition Intervention
Generalized Anxiety Disorder
Drug: escitalopram

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Amplitude Change of the Auditory Evoked N1 Component as a Predictor of Response to Escitalopram Treatment in Patients With Generalized Anxiety Disorder

Resource links provided by NLM:

Further study details as provided by Inje University:

Primary Outcome Measures:
  • Event related potential (ERP) N100 [ Time Frame: Baseline ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • - HAMA - HAMD - CGI - Beck Anxiety Inventory(self rating) [ Time Frame: baseline, 2, 4, 8 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 35
Study Start Date: December 2007
Study Completion Date: May 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GAD
35 patients with Generalized Anxiety disorder
Drug: escitalopram
  • Start with escitalopram 10mg
  • According to patient's symptoms, stay on 10mg or increase up to 20mg
  • Concomitant therapy : up to Xanax 0.5mg, or Ativan 1mg, not allowed above these dosages
  • Length of washout period will be at least 2 weeks for any psychotropic drugs
Other Name: lexapro


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • DSM-IV TR for GAD
  • Hamilton Rating Scale for Anxiety (HAMA) >18
  • 18 to 75 years old

Exclusion Criteria:

  • Severe medical illness
  • Other psychiatric illness
  • HAMD > 18
  • High suicidal risk
  • pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00613067

Korea, Republic of
Psychiatry department, Inje Univ. Ilsanpaik Hospital
Goyang, Kyunggi, Korea, Republic of, 414-410
Sponsors and Collaborators
Inje University
Principal Investigator: Seung-Hwan Lee, MD, PhD Psychiatry department, Inje Univ. Ilsanpaik Hospital
Study Director: Young-Min Park, MD, PhD Psychiatry department, Inje Univ. Ilsanpaik Hospital
Study Director: Sung-Man Bae, PhD Psychiatry department, Inje Univ. Ilsanpaik Hospital
  More Information

Additional Information:
Responsible Party: Seung-Hwan Lee, Department of Psychiatry, Inje Univ. Ilsanpaik Hospital Identifier: NCT00613067     History of Changes
Other Study ID Numbers: IB-0709-053 
Study First Received: January 29, 2008
Last Updated: June 29, 2010
Health Authority: South Korea: Korea Food and Drug Administration (KFDA)

Keywords provided by Inje University:
Generalized anxiety disorder
Central serotonergic activity

Additional relevant MeSH terms:
Anxiety Disorders
Pathologic Processes
Mental Disorders
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Autonomic Agents
Peripheral Nervous System Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents processed this record on October 27, 2016